Browse drugs

…city, with G3/4 events reported in 22% compared with 14% in the nivolumab monotherapy arm. An update presented at the European Society of…

…arm, 7.5% in the atezolizumab+bevacizumab arm, and 15.4% in the docetaxel (control) arm. There were no clear correlations of response or …

…state health sector in which several novel cancer drugs such as osimertinib, alectinib and immunotherapy are not approved for use in advanc…

…l lung cancer (ES-SCLC) provides only modest survival benefits. Tislelizumab has been recently approved by the European Commission, but head…

…rable (figure 2). Consistent with the tumor-activated design of vilastobart, treatment was generally well-tolerated: overall (n=44), 11 pat…

…s atezolizumab, followed by maintenance with DC vaccination and atezolizumab, led to long-term survival in a subset of patients with ES-SCLC…

…umab) are often used in ovarian and cervical cancers. ICIs (eg, pembrolizumab) are effective in mismatch repair-deficient endometrial cancer …

…mFOLFOX6 plus atezolizumab 840 mg Q2W for 12 cycles followed by atezolizumab monotherapy Q3W for 13 cycles (experimental). The primary end-p…

…the efficacy and safety of two cycles of induction therapy with bevacizumab and paclitaxel followed by atezolizumab and nab-paclitaxel comp…

…c-enhanced anti-CTLA-4 monoclonal antibody, in combination with atezolizumab in patients with advanced solid tumors and in MSS CRC. Journal …

…. For HCC-specific mortality, higher risks were associated with Lenvatinib (aHR 9.04; 95%CI 3.36-24.3; p<0.001), Sorafenib (aHR 5.82; 95%C…

…uced vessel density.Conclusion The combination of FAP-IL2v plus atezolizumab with or without bevacizumab was consistent with the known safet…